News: Dynavax Technologies Corp (DVAX.A)

DVAX.A on American Stock Exchange

2.48USD
20 May 2013
Price Change (% chg)

$-0.04 (-1.59%)
Prev Close
$2.52
Open
$2.51
Day's High
$2.51
Day's Low
$2.45
Volume
54,237
Avg. Vol
87,705
52-wk High
$5.08
52-wk Low
$1.75

Search Stocks
Select another date:

Mon, Feb 25 2013

Photo

Dynavax may have to repitch hepatitis B vaccine for smaller market

- Dynavax Technologies Inc may need to repitch its hepatitis B vaccine for a smaller patient population, after U.S. health regulators declined to approve the vaccine for adults - an estimated $700 million global market.

Continue Reading

BRIEF-Dynavax Technologies shares off 28 pct premarket

NEW YORK, Feb 25 - Dynavax Technologies Corp : * Shares off 28 percent after FDA rejects hep-b vaccine

UPDATE 2-Dynavax slides as FDA rejects adult hep B vaccine

Feb 25 - U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B vaccine and sought additional data to evaluate its safety, delaying the market entry of a faster-acting and less frequently needed vaccine for the liver-attacking infection.

FDA rejects Dynavax's adult hep B vaccine on safety concerns

Feb 25 - U.S. health regulators denied approval to Dynavax Technologies Inc's adult hepatitis B vaccine in its current form and asked for more data to evaluate the vaccine's safety.

Select another date:

Market Views

» More DVAX.A Market Views

Press Releases

Search Stocks